Identification of ABCC3 and its isoforms as potential biomarker in hepatocellular carcinoma

References

• Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V, Chiorino G, Akkaya BG, Linton KJ, De Laurenzi V, et al. 2019. ABCC3 is a novel target for the treatment of pancreatic cancer. Adv Biol Regul. 73:100634. doi: 10.1016/j.jbior.2019.04.004.
   PubMedGoogle Scholar
• Alarcón-Sánchez BR, Pérez-Carreón JI, Villa-Treviño S, Arellanes-Robledo J. 2021. Molecular alterations that precede the establishment of the hallmarks of cancer: an approach on the prevention of hepatocarcinogenesis. Biochem Pharmacol. 194:114818. doi: 10.1016/j.bcp.2021.114818.
   PubMed Web of Science ®Google Scholar
• Balaji SA, Udupa N, Chamallamudi MR, Gupta V, Rangarajan A. 2016. Role of the drug transporter ABCC3 in breast cancer chemoresistance. PLOS One. 11(5):e0155013. doi: 10.1371/journal.pone.0155013.
   PubMed Web of Science ®Google Scholar
• Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. 2016. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 30(6):836–848. doi: 10.1016/j.ccell.2016.10.009.
   PubMed Web of Science ®Google Scholar
• Carrasco-Torres G, Fattel-Fazenda S, López-Alvarez GS, García-Román R, Villa-Treviño S, Vásquez-Garzón VR. 2016. The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker. Tumour Biol. 37(2):2007–2014. doi: 10.1007/s13277-015-3999-5.
   PubMedGoogle Scholar
• Chai J, He Y, Cai S-Y, Jiang Z, Wang H, Li Q, Chen L, Peng Z, He X, Wu X, et al. 2012. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology. 55(5):1485–1494. doi: 10.1002/hep.24801.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19(8):649–658. doi: 10.1016/j.neo.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Chrostek L, Panasiuk A. 2014. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol. 20(25):8018–8023. doi: 10.3748/wjg.v20.i25.8018.
   PubMed Web of Science ®Google Scholar
• Cisneros-Garza LE, González-Huezo MS, López-Cossio JA, Kuljacha-Gastelum AL. 2018. Characterization of hepatocellular carcinoma in Mexico. Rev Gastroenterol Mex. 83(3):223–227. doi: 10.1016/j.rgmx.2017.06.003.
   Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. 2001. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11(7):1156–1166. doi: 10.1101/gr.184901.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran R, Bandoh S, Roberts LR. 2016. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 5:879. doi: 10.12688/f1000research.6946.1.
   Google Scholar
• Divella R, Mazzocca A, Daniele A, Sabbà C, Paradiso A. 2019. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. Int J Biol Sci. 15(3):610–616. doi: 10.7150/ijbs.29599.
   PubMed Web of Science ®Google Scholar
• Fromm MF, Leake B, Roden DM, Wilkinson GR, Kim RB. 1999. Human MRP3 transporter: identification of the 5′-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta. 1415(2):369–374. doi: 10.1016/s0005-2736(98)00233-8.
   PubMed Web of Science ®Google Scholar
• Gomez-Quiroz LE, Roman S. 2022. Influence of genetic and environmental risk factors in the development of hepatocellular carcinoma in Mexico. Ann Hepatol. 27(Suppl. 1):100649. doi: 10.1016/j.aohep.2021.100649.
   PubMedGoogle Scholar
• Greuter T, Shah VH. 2016. Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights. J Gastroenterol. 51(6):511–519. doi: 10.1007/s00535-016-1190-4.
   PubMed Web of Science ®Google Scholar
• Guan M-C, Ouyang W, Wang M-D, Liang L, Li N, Fu T-T, Shen F, Lau W-Y, Xu Q-R, Huang D-S, et al. 2021. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol. 13(5):351–365. doi: 10.4251/wjgo.v13.i5.351.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ. 2011. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos. 39(12):2395–2402. doi: 10.1124/dmd.111.041012.
   PubMed Web of Science ®Google Scholar
• Huang W, Chen K, Lu Y, Zhang D, Cheng Y, Li L, Huang W, He G, Liao H, Cai L, et al. 2021. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia. 23(12):1227–1239. doi: 10.1016/j.neo.2021.11.002.
   PubMed Web of Science ®Google Scholar
• Lapitz A, Arbelaiz A, Olaizola P, Aranburu A, Bujanda L, Perugorria MJ, Banales JM. 2018. Extracellular vesicles in hepatobiliary malignancies. Front Immunol. 9:2270. doi: 10.3389/fimmu.2018.02270.
   PubMed Web of Science ®Google Scholar
• Lee YT, Tran BV, Wang JJ, Liang IY, You S, Zhu Y, Agopian VG, Tseng HR, Yang JD. 2021. The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma. Cancers. 13(12):3076. doi: 10.3390/cancers13123076.
   PubMed Web of Science ®Google Scholar
• Li S, Chen L. 2022. Exosomes in pathogenesis, diagnosis, and treatment of hepatocellular carcinoma. Front Oncol. 12:793432. doi: 10.3389/fonc.2022.793432.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Macias RIR, Monte MJ, Romero MR, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano AG, Espinosa-Escudero R, Reviejo M, et al. 2020. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers. 12(6):1663. doi: 10.3390/cancers12061663.
   PubMed Web of Science ®Google Scholar
• Meng X, Dong S, Yangyang L, Wang S, Xu X, Liu T, Zhuang X. 2022. Adenosine triphosphate-binding cassette subfamily C members in liver hepatocellular carcinoma: bioinformatics-driven prognostic value. Medicine. 101(7):e28869. doi: 10.1097/MD.0000000000028869.
   PubMed Web of Science ®Google Scholar
• Momen-Heravi F, Bala S, Kodys K, Szabo G. 2015. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. Sci Rep. 5(1):9991. doi: 10.1038/srep09991.
   PubMedGoogle Scholar
• More VR, Cheng Q, Donepudi AC, Buckley DB, Lu ZJ, Cherrington NJ, Slitt AL. 2013. Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver. Drug Metab Dispos. 41(5):1148–1155. doi: 10.1124/dmd.112.049676.
   PubMed Web of Science ®Google Scholar
• Nies AT, König J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. 2001. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer. 94(4):492–499. doi: 10.1002/ijc.1498.
   PubMed Web of Science ®Google Scholar
• Pan Y, Chen H, Yu J. 2020. Biomarkers in hepatocellular carcinoma: current status and future perspectives. Biomedicines. 8(12):576. doi: 10.3390/biomedicines8120576.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al. 2022. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 76(3):681–693. doi: 10.1016/j.jhep.2021.11.018.
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, Scheper RJ. 2002. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest. 82(2):193–201. doi: 10.1038/labinvest.3780411.
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9(7):671–675. doi: 10.1038/nmeth.2089.
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, Llovet JM. 2017. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 152(4):745–761. doi: 10.1053/j.gastro.2016.11.048.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1):W98–W102. doi: 10.1093/nar/gkx247.
   PubMed Web of Science ®Google Scholar
• Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al. 2018. Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 7(1):1535750. doi: 10.1080/20013078.2018.1535750.
   PubMed Web of Science ®Google Scholar
• Thietart S, Rautou PE. 2020. Extracellular vesicles as biomarkers in liver diseases: a clinician’s point of view. J Hepatol. 73(6):1507–1525. doi: 10.1016/j.jhep.2020.07.014.
   PubMed Web of Science ®Google Scholar
• Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, et al. 2016. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget. 7(6):7207–7215. doi: 10.18632/oncotarget.6889.
   PubMedGoogle Scholar
• Tress ML, Abascal F, Valencia A. 2017. Alternative splicing may not be the key to proteome complexity. Trends Biochem Sci. 42(2):98–110. doi: 10.1016/j.tibs.2016.08.008.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. 2015. Proteomics. Tissue-based map of the human proteome. Science. 347(6220):1260419. doi: 10.1126/science.1260419.
   PubMed Web of Science ®Google Scholar
• UniProt. 2022. O15438·MRP3_HUMAN. https://www.uniprot.org/uniprotkb/O15438/entry.
   Google Scholar
• Uzzaman A, Zhang X, Qiao Z, Zhan H, Sohail A, Wahid A, Shang Z, Guan X, Cao CX, Xiao H. 2020. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer. Biochimie. 177:132–141. doi: 10.1016/j.biochi.2020.08.013.
   PubMed Web of Science ®Google Scholar
• Vásquez-Garzón VR, Beltrán-Ramírez O, Salcido-Neyoy ME, Cervante-Anaya N, Villa-Treviño S. 2015. Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model. Biomed Rep. 3(2):167–172. doi: 10.3892/br.2014.411.
   PubMedGoogle Scholar
• Wu Q, Zhou L, Lv D, Zhu X, Tang H. 2019. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. 12(1):53. doi: 10.1186/s13045-019-0739-0.
   PubMedGoogle Scholar
• Zhao Y, Lu H, Yan A, Yang Y, Meng Q, Sun L, Pang H, Li C, Dong X, Cai L. 2013. ABCC3 as a marker for multidrug resistance in non-small cell lung cancer. Sci Rep. 3(1):3120. doi: 10.1038/srep03120.
   PubMedGoogle Scholar
• Zúñiga-García V, Chávez-López MdG, Quintanar-Jurado V, Gabiño-López NB, Hernández-Gallegos E, Soriano-Rosas J, Pérez-Carreón JI, Camacho J. 2015. Differential expression of ion channels and transporters during hepatocellular carcinoma development. Dig Dis Sci. 60(8):2373–2383. doi: 10.1007/s10620-015-3633-9.
   PubMed Web of Science ®Google Scholar